aTyr Pharma Statistics

Total Valuation

aTyr Pharma has a market cap or net worth of $457.48 million. The enterprise value is $394.12 million.

Market Cap	457.48M
Enterprise Value	394.12M

Important Dates

The last earnings date was Wednesday, May 7, 2025, after market close.

Earnings Date	May 7, 2025
Ex-Dividend Date	n/a

Share Statistics

aTyr Pharma has 89.00 million shares outstanding. The number of shares has increased by 33.04% in one year.

Current Share Class	89.00M
Shares Outstanding	89.00M
Shares Change (YoY)	+33.04%
Shares Change (QoQ)	+4.55%
Owned by Insiders (%)	2.27%
Owned by Institutions (%)	70.30%
Float	86.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	6.10
P/TBV Ratio	6.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.17.

Current Ratio	7.79
Quick Ratio	7.24
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -79.70% and return on invested capital (ROIC) is -45.00%.

Return on Equity (ROE)	-79.70%
Return on Assets (ROA)	-39.82%
Return on Invested Capital (ROIC)	-45.00%
Return on Capital Employed (ROCE)	-77.46%
Revenue Per Employee	n/a
Profits Per Employee	-$975,569
Employee Count	65
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +180.87% in the last 52 weeks. The beta is 0.87, so aTyr Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	+180.87%
50-Day Moving Average	3.83
200-Day Moving Average	3.28
Relative Strength Index (RSI)	61.52
Average Volume (20 Days)	2,427,687

Short Selling Information

The latest short interest is 13.77 million, so 15.47% of the outstanding shares have been sold short.

Short Interest	13.77M
Short Previous Month	12.68M
Short % of Shares Out	15.47%
Short % of Float	15.83%
Short Ratio (days to cover)	9.72

Income Statement

Revenue	n/a
Gross Profit	-52.82M
Operating Income	-67.05M
Pretax Income	-53.93M
Net Income	-63.41M
EBITDA	-66.35M
EBIT	-67.05M
Earnings Per Share (EPS)	-$0.80

Full Income Statement

Balance Sheet

The company has $76.35 million in cash and $12.99 million in debt, giving a net cash position of $63.36 million or $0.71 per share.

Cash & Cash Equivalents	76.35M
Total Debt	12.99M
Net Cash	63.36M
Net Cash Per Share	$0.71
Equity (Book Value)	74.86M
Book Value Per Share	0.84
Working Capital	72.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$62.16 million and capital expenditures -$48,000, giving a free cash flow of -$62.21 million.

Operating Cash Flow	-62.16M
Capital Expenditures	-48,000
Free Cash Flow	-62.21M
FCF Per Share	-$0.70

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

aTyr Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-33.04%
Shareholder Yield	-33.04%
Earnings Yield	-13.86%
FCF Yield	-13.60%

Analyst Forecast

The average price target for aTyr Pharma is $18.60, which is 261.87% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$18.60
Price Target Difference	261.87%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 1, 2019. It was a reverse split with a ratio of 0.0714285:1.

Last Split Date	Jul 1, 2019
Split Type	Reverse
Split Ratio	0.0714285:1

Scores

aTyr Pharma has an Altman Z-Score of -3.89 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.89
Piotroski F-Score	2